TABLE 4.
Baseline and clinical characteristics among patients who switched treatment and who did not switch treatment.
| Variable | Category, n (%) | RCT | OC | ||
|---|---|---|---|---|---|
| Patients who switched treatment | Patients who did not switch treatment | Patients who switched treatment | Patients who did not switch treatment | ||
| N = 449 (52.9%) | N = 400 (47.1%) | N = 1881 (56.3%) | N = 1459 (43.7%) | ||
| Age | <65 | 227 (50.6) | 207 (51.9) | 708 (37.6) | 514 (35.2) |
| 65–75 | 179 (39.9) | 143 (35.8) | 717 (38.1) | 551 (37.8) | |
| ≥75 | 43 (9.6) | 49 (12.3) | 456 (24.2) | 394 (27.0) | |
| Histology | Non-squamous | 251 (55.9) | 258 (64.5) | 1287 (68.4) | 991 (67.9) |
| Squamous | 198 (44.1) | 142 (35.5) | 594 (31.6) | 468 (32.1) | |
| Treatment | Carboplatin + Pacli/Nab-pacli | 287 (63.9) | 281 (58.5) | 1034 (55.0) | 843 (57.8) |
| Platinum + Pemetrexed | 162 (36.1) | 119 (41.5) | 847 (45.0) | 616 (42.2) | |
| Progression during the follow-up a | Yes | 390 (86.9) | 230 (57.5) | 1360 (72.3) | 397 (27.2) |
| No | 59 (13.1) | 170 (42.5) | 521 (27.7) | 1062 (72.8) | |
Notes: OC, observational comparator; RCT, randomized clinical trial.
a
Follow-up is up to switch or, in absence of switch until last activity before study end date (end date for the specific data source).